- Home
- JELD vs HURA Comparison
JELD vs HURA Comparison
Compare JELD & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JELD | HURA |
|---|---|---|
| Founded | 1960 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 160.5M |
| IPO Year | 2016 | 2010 |
Fundamental Metrics
Financial Performance| Metric | JELD | HURA |
|---|---|---|
| Price | $1.38 | $1.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $1.93 | ★ $8.04 |
| AVG Volume (30 Days) | ★ 1.5M | 202.1K |
| Earning Date | 11-02-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.41 |
| 52 Week High | $4.92 | $3.43 |
Technical Indicators
Market Signals| Indicator | JELD | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.67 | 36.09 |
| Support Level | $1.31 | $1.27 |
| Resistance Level | $2.18 | $1.83 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 13.46 | 2.74 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.